Table 2.
Characteristics of the included studies: chemotherapy-induced nausea and vomiting (CINV).
| Author | Sample size (M/F) Cancer type |
Intervention (n) | Control (n) | Outcome measures | Result | |
|---|---|---|---|---|---|---|
| Intervention | Control | |||||
| Liu et al. 2011 [24] | 51 (27/24) Hematologic cancer |
Promethazine (25 mg) injection at bilateral ST36 (n = 26) | Metoclopramide (10 mg), IV (n = 25) | Responder rate (%)a | 96.2%* | 68% |
| Yang et al. 2011 [25] | 96 (50/46) Various |
Metoclopramide (10 mg) injection at bilateral ST36 (n = 50) 0.5 h before chemotherapy, qd |
Tropisetron (5 mg), IV (n = 46) 0.5 h before chemotherapy, bid |
Responder rate (%)b | 78%* | 52.1% |
| You et al. 2009 [26] | 142 (0/142) Ovarian cancer |
Vit. B6 (50 mg) injection and MA at bilateral PC6 (n = 46) qod |
(1) Vit. B6 (50 mg), IM (n = 46) bid (2) MA at bilateral PC6 (n = 45) qod |
(A) Total number of emesis episodes in 21 days (mean, 95% CI) (B) Proportion of emesis free days in 21 days (%, mean, 95% CI) |
(A) 5.9, 3.8–7.0** (B) 59%, 48–69** |
(1) (A) 13.2, 9.4–15.0 (B) 21%, 12–28 (2) (A) 10.6, 7.4–11.8 (B) 30%, 21–39 |
| Chen 2007 [27] | 258 (0/258) Ovarian cancer |
Metoclopramide injection (n = 98) 10 mg, at left PC6 and CV10, 15 min before chemotherapy 10 mg, at right PC6 and CV 10 after chemotherapy |
(1) Metoclopramide, IV (n = 74) 20 mg each, before and after chemotherapy (2) Granisetron (3 mg), IV (n = 86) before chemotherapy |
Responder rate (%)c | 95%** | (1) 40.5% (2) 96.5% |
| Hu 2003 [28] | 123 (86/37) Various |
Huangqi or Danggui (4 mL) injection, alternately at bilateral ST36, SP10, and BL23 (n = 71) qd |
Batilol (50 mg), leucogen (20 mg) and Vit. B6 (20 mg), po (n = 52) tid |
Responder rate (%)b | 71.8%** | 44.2% |
| Tao et al. 2000 [29] | 480 (343/137) Various |
Metoclopramide (5 mg) and diazepam (1.25 mg) injection alternately at bilateral PC6 and ST36 (n = 160) 30 min before chemotherapy Metoclopramide (10 mg) after chemotherapy |
(1) Metoclopramide (20 mg) and diazepam (5 mg), IV (n = 160) 30 min before chemotherapy Metoclopramide (20 mg) after chemotherapy (2) Ondansetron, IV (n = 160) 8 mg, 30 min before chemotherapy 8 mg, after chemotherapy |
Responder rate (%)d | 98.8%** | (1) 43.1% (2) 94.4% |
AEs: adverse events; bid: twice a day; CI: confidence interval; h: hour(s); IM: intramuscular injection; IV: intravenous injection; MA: manual acupuncture; min: minute(s); NR: not reported; po: orally; qd: everyday; qod: every other day; Vit.: vitamin; WHO: World Health Organization.
Acupuncture point ST36 refers to 36th point of stomach meridian and extra points have different nomenclature (e.g., Ex-UE7 means 7th extra point in upper extremity).
aResponder rate: (number of participants with any improvement from the intervention/total number of participants) ∗ 100(%).
bResponder rate: (number of participants with WHO grade [30] 0 + 1/total number of participants) ∗ 100(%).
cResponder rate: (number of participants with less than four emesis episodes per day/total number of participants) ∗ 100(%).
dResponder rate: (number of participants with less than three emesis episodes per day/total number of participants)∗100 (%).
*P < 0.05; **P < 0.01.